Pembrolizumab Combo Enhances Response Rate in ER+/HER2– Breast Cancer
Adding pembrolizumab (Keytruda) to neoadjuvant chemotherapy elicited a statistically significant improvement in pathological complete response (pCR) vs placebo in patients with previously untreated estrogen receptor (ER)–positive/HER2-negative grade 3 …